EP2200627A4 - Methods and compositions for treating melanoma - Google Patents

Methods and compositions for treating melanoma

Info

Publication number
EP2200627A4
EP2200627A4 EP07814876A EP07814876A EP2200627A4 EP 2200627 A4 EP2200627 A4 EP 2200627A4 EP 07814876 A EP07814876 A EP 07814876A EP 07814876 A EP07814876 A EP 07814876A EP 2200627 A4 EP2200627 A4 EP 2200627A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
treating melanoma
melanoma
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07814876A
Other languages
German (de)
French (fr)
Other versions
EP2200627A1 (en
Inventor
James S Goydos
Suzie Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of EP2200627A1 publication Critical patent/EP2200627A1/en
Publication of EP2200627A4 publication Critical patent/EP2200627A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07814876A 2007-09-14 2007-09-14 Methods and compositions for treating melanoma Withdrawn EP2200627A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/078550 WO2009035460A1 (en) 2007-09-14 2007-09-14 Methods and compositions for treating melanoma

Publications (2)

Publication Number Publication Date
EP2200627A1 EP2200627A1 (en) 2010-06-30
EP2200627A4 true EP2200627A4 (en) 2013-01-09

Family

ID=40452289

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07814876A Withdrawn EP2200627A4 (en) 2007-09-14 2007-09-14 Methods and compositions for treating melanoma

Country Status (3)

Country Link
EP (1) EP2200627A4 (en)
AU (1) AU2007358742A1 (en)
WO (1) WO2009035460A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173644A2 (en) * 2012-05-16 2013-11-21 John Wayne Cancer Institute Immunological markers for adjuvant therapy in melanoma

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATALLAH EHAB ET AL: "Treatment of metastatic malignant melanoma.", CURRENT TREATMENT OPTIONS IN ONCOLOGY MAY 2005, vol. 6, no. 3, May 2005 (2005-05-01), pages 185 - 193, XP002688037, ISSN: 1527-2729 *
EISEN T ET AL: "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis", BRITISH JOURNAL OF CANCER, vol. 95, no. 5, September 2006 (2006-09-01), pages 581 - 586, XP002688038, ISSN: 0007-0920 *
HAAS HELGA SUSANNE ET AL: "The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma", ONCOLOGY REPORTS, vol. 17, no. 6, June 2007 (2007-06-01), pages 1399 - 1404, XP002688036, ISSN: 1021-335X *
PATRICK TERHEYDEN ET AL: "Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER, BERLIN, DE, vol. 133, no. 11, 22 June 2007 (2007-06-22), pages 897 - 901, XP019542595, ISSN: 1432-1335, DOI: 10.1007/S00432-007-0251-8 *
See also references of WO2009035460A1 *

Also Published As

Publication number Publication date
WO2009035460A1 (en) 2009-03-19
AU2007358742A1 (en) 2009-03-19
EP2200627A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
HRP20190214T1 (en) Compositions and methods for treating purpura
EP2170309A4 (en) Methods and compositions for treating disorders
ZA201001300B (en) Antigen-asjuvant compositions and methods
EP2214707A4 (en) Compositions and methods for treating inflammation
SI2137210T1 (en) Novel method and compositions
IL202015A0 (en) Methods and compositions for treating skin conditions
EP2120561A4 (en) Compositions for treating biofilms and methods for using same
IL210153A0 (en) Nutrigenomics methods and compositions
EP2271218A4 (en) Use and composition for treating dementia
IL212822A0 (en) Anti-cxcr1 compositions and methods
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2282719A4 (en) Compositions and methods for treating multiple sclerosis
GB0819530D0 (en) Methods and compositions
EP2355660A4 (en) Compositions and methods for treating multiple sclerosis
GB0721291D0 (en) Methods and compositions
HRP20130642T1 (en) Methods and compositions for treating cancers
EP2271370A4 (en) Compositions and methods for diagnosing and treating melanoma
GB0719526D0 (en) Compositions and methods
EP2170314A4 (en) Methods and compositions for treating phenylketonuria
EP2200627A4 (en) Methods and compositions for treating melanoma
GB0811250D0 (en) Methods and compositions
GB0724549D0 (en) Compositions and methods
GB0723775D0 (en) Methods and compositions
GB0717683D0 (en) Compositions and methods
GB0707188D0 (en) Novel method and compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100412

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/197 20060101ALI20121128BHEP

Ipc: A61P 35/00 20060101ALI20121128BHEP

Ipc: A61K 31/365 20060101ALI20121128BHEP

Ipc: A61K 31/428 20060101AFI20121128BHEP

Ipc: A61K 45/06 20060101ALI20121128BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20121207

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130713